LGI1 and viral encephalitis: Notably, escalating to second-line treatment was later in our cases than in those described by other authors in anti-NMDAR encephalitis (median 54 days), but without substantial differences if compared to the timing reported in anti-LGI1, CASPR2, or GAD65 encephalitis (median 155, 632, and 1209 days) [9].